| |
ReCap is a great resource. It is frequently off a bit or missing stuff, however.....
"This strategy has enabled the
development of a broad pipeline of royalty bearing product
opportunities led
by CP358,774, an anti-cancer compound, which is currently in large
scale Phase II trials funded and managed by Pfizer."
biz.yahoo.com
Friday November 6, 12:18 pm Eastern Time
Pfizer unveils raft of early stage Rx drugs
NEW YORK, Nov 6 (Reuters) - Pfizer Inc. disclosed on Friday a plethora
of
early-stage experimental drugs, which the company said it hopes will
make
Pfizer the world's premier pharmaceutical company by the early 21st
century.
Meanwhile, Pfizer executives said they were comfortable that they will
deliver diluted per share earnings of $1.95 to $2.00 from continuing
operations, excluding nonrecurring and special items, in 1998. And they
said
Pfizer would likely have earnings growth in the fourth quarter of 1998
stronger than that seen in the third quarter.
In an unusual move, Pfizer senior scientist John Niblack, unveiled the
names
and characteristics of many drugs that are currently in preclinical
animal
testing or being studied in human Phase I and Phase II clinical trials.
Pfizer said that at least several of the more promising early-stage
compounds were cancer drugs being developed in collaboration with OSI
Pharmaceuticals Inc (Nasdaq:OSIP - news). (snip) |
|
